Arcturus Therapeutics Holdings Inc. Share Price & Technical Analysis
ARCT · $7.03 (+0.14%)
Healthcare / Biotechnology
$7.03
+0.14%
Arcturus Therapeutics Holdings Inc., a messenger RNA medicines company, focuses on the development of liver and respiratory rare disease therapeutics. Its technology platforms include STARR, a self-amplifying mRNA technology platform, and LUNAR, a lipid-mediated delivery system. The company also develops ARCT-032 (LUNAR-CF), an mRNA therapeutic candidate for cystic fibrosis that is in Phase 2 clin…
Price chart
Seasonality
May has 3 positive and 2 negative years (last 5 years shown)
-19% return in May, 18% avg return in past 3 year May month.
18% return in 2026, 0% avg return in past 3 years.
Swipe sideways to see all months →
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Yr | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26 | 21% | 11% | -4% | 9% | -19% | – | – | – | – | – | – | – | 18% |
| 25 | -1% | 2% | -38% | 22% | -2% | 1% | -6% | 42% | 8% | -48% | -33% | -8% | -61% |
| 24 | 4% | 17% | -13% | -24% | 52% | -39% | -2% | -9% | 10% | -23% | 1% | -7% | -33% |
| 23 | 23% | -23% | 49% | 13% | 3% | 5% | 22% | -14% | -17% | -25% | 24% | 34% | 93% |
| 22 | -30% | -10% | 17% | -29% | 3% | -21% | 11% | -19% | 3% | 18% | 3% | -7% | -60% |
Monthly return % by calendar month · historical pattern, not a forecast
Bearish · Downtrend · Weak
Arcturus Therapeutics Holdings Inc., a messenger RNA medicines company, focuses on the development of liver and respiratory rare disease therapeutics. Its technology platforms include STARR, a self-amplifying mRNA technology platform, and LUNAR, a lipid-mediated delivery system. The company also develops ARCT-032 (LUNAR-CF), an mRNA therapeutic candidate for cystic fibrosis that is in Phase 2 clinical development; and ARCT-810 (LUNAR-OTC), which is in Phase 2 clinical development to address ornithine transcarbamylase (OTC) deficiency. In addition, it develops KOSTAIVE, a self-amplifying RNA vaccine for COVID-19; ARCT-2138 (LUNAR-FLU), which is in Phase1 clinical trial for the treatment of seasonal influenza; and ARCT-2304 (LUNAR-H5N1) that is in Phase1 clinical trial for the treatment of Pandemic Influenza. Arcturus Therapeutics Holdings Inc. was founded in 2013 and is headquartered in San Diego, California.
Full AI Q&A, portfolio tracking, and live alerts in the app.
Key metrics
Market cap
$235.20M
P/E ratio
—
52W high
$24.17
52W low
$5.85
Volume
2,66,400
Beta
2.42
Related stocks in Healthcare
Merck & Co Inc Cedear (5…
₹32,900
Abbott Laboratories Cede…
₹30,500
Eli Lilly And Company Ce…
₹25,540
Unitedhealth Group Inc C…
₹17,200
₹6,600
Frequently asked questions
- What is Arcturus Therapeutics Holdings Inc. share price today?
- Arcturus Therapeutics Holdings Inc. (ARCT) last traded around $7.03 on StockPro. Prices refresh every few minutes during market hours.
- What technical signals does ARCT have?
- StockPro monitors breakouts, volume spikes, EMA reversals, and momentum for ARCT. Download the app for real-time alerts.
- How can I analyze Arcturus Therapeutics Holdings Inc. stock?
- Use the price chart, seasonality heatmap, key metrics, and AI insight on this page. For portfolio tracking and push alerts, download StockPro on Android or iOS.